clinical trial · NCT07582237
Long-Term Follow-up Study of FURESTEM-AD in Patients With Atopic Dermatitis(K0106)
Kang Stem Biotech Co., Ltd.·—·active not recruiting·n = 262
Dermatitis, Atopic
brief summary
Long-Term Follow-up Study of Subjects With Moderate to Severe Chronic Atopic Dermatitis Who Had Administered FURESTEM-AD Inj. in K0106 Study
started
Oct 5, 2021
primary completion
Aug 21, 2028
completion
Feb 21, 2029
last updated
May 12, 2026
official title
Long-Term Follow-up Study of Subjects With Moderate to Severe Chronic Atopic Dermatitis Who Had Administered FURESTEM-AD Inj. in K0106 Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol